KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) EBT Margin (2016 - 2025)

Historic EBT Margin for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to 134.05%.

  • Bio-Rad Laboratories' EBT Margin rose 2702100.0% to 134.05% in Q4 2025 from the same period last year, while for Dec 2025 it was 38.54%, marking a year-over-year increase of 1298100.0%. This contributed to the annual value of 38.54% for FY2025, which is 1298100.0% up from last year.
  • Latest data reveals that Bio-Rad Laboratories reported EBT Margin of 134.05% as of Q4 2025, which was up 2702100.0% from 66.02% recorded in Q3 2025.
  • Bio-Rad Laboratories' EBT Margin's 5-year high stood at 672.32% during Q3 2021, with a 5-year trough of 623.92% in Q1 2022.
  • For the 5-year period, Bio-Rad Laboratories' EBT Margin averaged around 14.13%, with its median value being 17.97% (2025).
  • As far as peak fluctuations go, Bio-Rad Laboratories' EBT Margin plummeted by -8024000bps in 2022, and later soared by 6364500bps in 2023.
  • Quarter analysis of 5 years shows Bio-Rad Laboratories' EBT Margin stood at 276.62% in 2021, then skyrocketed by 154bps to 149.45% in 2022, then crashed by -58bps to 62.89% in 2023, then crashed by -317bps to 136.16% in 2024, then soared by 198bps to 134.05% in 2025.
  • Its EBT Margin stands at 134.05% for Q4 2025, versus 66.02% for Q3 2025 and 63.54% for Q2 2025.